Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides

US6319912A · kind A · utility

Assignees

• Amerimas Home Products, Inc. · US
• Ligand Pharmaceuticals Incorporated · US

Inventors

• Gary S. Grubb · Newtown Square, US
• Lin Zhi · San Diego, US
• Todd K. Jones · Solana Beach, US
• James P. Edwards · San Diego, US
• Christopher M. Tegley · Thousand Oaks, US
• Mark A. Collins · Norristown, US
• Valerie A. Mackner · Conshohocken, US
• Jay E. Wrobel · Lawrenceville, US

Key dates

• Filing date: Apr 19, 2000
• Grant date: Nov 20, 2001
• Expiry date: Apr 19, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P15/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to cyclic combination therapies utilizing, in combination with a progestin, an estrogen, or both, progesterone receptor antagonists of the general structure: ##STR1## wherein the substituents are as defined herein, or pharmaceutically acceptable salt thereof.